Abstract:Whether drugs that enhance cognition in healthy individuals will appear in the near future has become a topic of considerable interest. We address this possibility using a three variable system (psychological effect, neurobiological mechanism, and efficiency vs. capabilities) for classifying candidates. Ritalin and modafinil, two currently available compounds, operate on primary psychological states that in turn affect cognitive operations (attention and memory), but there is little evidence that these effects translate into improvements in complex cognitive processing. A second category of potential enhancers includes agents that improve memory encoding, generally without large changes in primary psychological states. Unfortunately, there is little information on how these compounds affect cognitive performance in standard psychological tests. Recent experiments have identified a number of sites at which memory drugs could, in principle, manipulate the cell biological systems underlying the learning-related long-term potentiation (LTP) effect; this may explain the remarkable diversity of memory promoting compounds. Indeed, many of these agents are known to have positive effects on LTP. A possible third category of enhancement drugs directed specifically at integrated cognitive operations is nearly empty. From a neurobiological perspective, two plausible candidate classes have emerged that both target the fast excitatory transmission responsible for communication within cortical networks. One acts on nicotinic receptors (alpha7 and alpha4) that regulate release of the neurotransmitter glutamate while the other ('ampakines') allosterically modulates the glutamate receptors mediating the post-synaptic response (EPSCs). Brain imaging in primates has shown that ampakines expand cortical networks engaged by a complex task; coupled with behavioral data, these findings provide evidence for the possibility of generating new cognitive capabilities. Finally, we suggest that continuing advances in behavioral sciences provide new opportunities for translational work, and that discussions of the social impact of cognitive enhancers have failed to consider the distinction between effects on efficiency vs. new capabilities.

Cognition Enhancement Strategies

Pharmacological enhancement of memory or cognition in normal subjects

Calmodulin Shuttling Mediates Cytonuclear Signaling to Trigger Experience-Dependent Transcription and Memory

A Novel Conditional Genetic System Reveals That Increasing Neuronal Camp Enhances Memory and Retrieval

Neurochemical Mechanisms of a Novel Alzheimer′s Disease Therapeutics on Improvement of Cognition and Depressive Behavior

The NMDA receptor as a target for cognitive enhancement

Drug targets for cognitive enhancement in neuropsychiatric disorders

Cognitive enhancers: Focus on modulatory signaling influencing memory consolidation

Neurochemical mechanisms of a novel Alzheimer's disease therapeutics on improvement of cognition and depressive behavior]

The likelihood of cognitive enhancement

Modulation of Long-Term Potentiation in the Hippocampus by Pharmacological Approach： A Novel Strategy for the Development of Cognitive Enhancers

Cognitive Enhancers in Theory and Practice: Studies of the Cholinergic Hypothesis of Cognitive Deficits in Alzheimer'S Disease

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy

Signaling pathways relevant to cognition-enhancing drug targets

Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways

Hacking the Brain: Dimensions of Cognitive Enhancement

Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors

The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people

Cellular Mechanisms of Cognitive Enhancement: The In Vivo Modulation of the Firing Activity and the Responsiveness of Rat Hippocampal Neurons by Memantine and Alpha7 Nicotinic Acetylcholine Receptor Ligands

Nanoparticle-Based Drug Delivery Systems Enhance Treatment of Cognitive Defects